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Abstract
Koi herpes virus (KHV) disease has been assessed according to the criteria of the Animal Health Law
(AHL), in particular criteria of Article 7 on disease profile and impacts, Article 5 on the eligibility of KHV
disease to be listed, Article 9 for the categorisation of KHV disease according to disease prevention
and control rules as in Annex IV and Article 8 on the list of animal species related to KHV disease. The
assessment has been performed following a methodology composed of information collection and
compilation, expert judgement on each criterion at individual and, if no consensus was reached before,
also at collective level. The output is composed of the categorical answer, and for the questions where
no consensus was reached, the different supporting views are reported. Details on the methodology
used for this assessment are explained in a separate opinion. According to the assessment performed,
it is inconclusive whether KHV disease can be considered eligible to be listed for Union intervention as
laid down in Article 5(3) of the AHL because there was no full consensus on the criterion 5 A(v).
Consequently, the assessment on compliance of KHV disease with the criteria as in Annex IV of the
AHL, for the application of the disease prevention and control rules referred to in Article 9(1) is also
inconclusive, as well as which animal species can be considered to be listed for KHV disease according
to Article 8(3) of the AHL.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in section 1.2 of the scientific opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in section 1.2 of the scientific opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL)
framework (EFSA AHAW Panel, 2017).
The present document reports the results of assessment on Koi herpes virus (KHV) disease
according to the criteria of the AHL articles as follows:
• Article 7: Koi herpes virus (KHV) disease profile and impacts
• Article 5: eligibility of Koi herpes virus (KHV) disease to be listed
• Article 9: categorisation of Koi herpes virus (KHV) disease according to disease prevention and
control rules as in Annex IV
• Article 8: list of animal species related to Koi herpes virus (KHV) disease.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of KHV disease according to the Article 7 criteria of the AHL
and related parameters [see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)], based
on the information contained in the fact-sheet as drafted by the selected disease scientist (see section
2.1 of the scientific opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Profile
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Koi herpes virus disease (KHVD) is caused by Cyprinid Herpes Virus-3 (CyHV-3) which is otherwise
known as Koi herpes virus (KHV). This is a DNA virus from the Alloherpesvirus family which
predominantly affects common carp (Cyprinus carpio, family: Cyprinidae, order: Cypriniformes) and its
varieties (OIE, online).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Common carp (Cyprinus carpio, family: Cyprinidae, order: Cypriniformes) and its varieties (OIE,
online).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Common carp (Cyprinus carpio, family: Cyprinidae, order: Cypriniformes) and its varieties. Mortality
also observed in hybrids of carp 9 goldfish (Carassius auratus, family: Cyprinidae, order:
Cypriniformes) and carp 9 crucian carp (Carassius carassius, family: Cyprinidae, order: Cypriniformes)
(Hedrick et al., 2006; Bergmann et al., 2010b).
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Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Common carp (Cyprinus carpio, family: Cyprinidae, order: Cypriniformes) and its varieties. Mortality
also observed in hybrids of carp 9 goldfish (Carassius auratus, family: Cyprinidae, order:
Cypriniformes) and carp 9 crucian carp (Carassius carassius, family: Cyprinidae, order: Cypriniformes)
(Hedrick et al., 2006; Bergmann et al., 2010b).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
KHV nucleic acids have been detected by polymerase chain reaction (PCR) in freshwater mussels
and crustacea. Cohabitation experiments suggest asymptomatic infection of goldfish, tench (Tinca
tinca), vimba (Vimba spp.), common bream (Abramis brama), common roach (Rutilus rutilus),
European perch (Perca fluviatilis), ruffe (Gymnocephalus cernua), gudgeon (Gobioninae), rudd
(Scardinius erythrophthalmus), northern pike (Esox Lucius), Prussian carp (Carassius gibelio), silver
carp (Hypophthalmichthys molitrix) and grass carp (Ctenopharyngodon idella) that can subsequently
transmit to na€ıve carp (El-Matbouli et al., 2007; Kempter and Bergmann, 2007; Kempter et al., 2009;
Kielpinski et al., 2010; El-Matbouli and Soliman, 2011; Kempter et al., 2012; Fabian et al., 2013;
Radosavljevic et al., 2012). The World Organization for Animal Health (OIE, online) also lists goldfish,
grass carp, ide (Leuciscus idus), catfish, Russian sturgeon (Acipenser gueldenstaedtii) and Atlantic
sturgeon (Acipenser oxyrinchus) as carrier species.
Parameter 6 – Domestic reservoir species (or family/orders)
Goldfish (Carassius auratus, family: Cyprinidae, order: Cypriniformes) (Bergmann et al., 2010a).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
Limited information is available, and there is a knowledge gap in terms of acquiring this information
at the national level. Some case study based data has been reported from a variety of countries. A
serological survey by Taylor et al. (2010a) suggests that in the UK between 85% and 93% of the
population in lakes with clinically affected carps tested positive for KHV antibodies (Taylor et al.,
2010a). In lakes and farms where no clinical disease has been observed seroprevalences ranged
between 5% and 25% (mean = 14.75%, median = 14%). In lake Biwa, Japan, 54% of the carp
population tested antibody positive for KHV after a disease outbreak in 2006 (Uchii et al., 2009).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
With respect to prevalence and mortality, there are also knowledge gaps at the national level, with
little data available to determine morbidity in farms or lakes across the European Union (EU). However,
100% morbidity has been observed in experimental studies on carp (Haenen et al., 2004; Bergmann
et al., 2010b).
Mortality
Parameter 3 – Case-fatality rate
In experimental studies on carp, 70–80% mortality has been observed (Haenen et al., 2004;
Bergmann et al., 2010b). However, in the case of natural infections, there is a knowledge gap relating
to observed mortality rates. Several studies suggest that mortality due to KHV (in lake and farm
systems) can be high. However, no reliable estimates of mortality rates are available in outbreak sites
in Europe and elsewhere, due to difficulties in determining the total host population size. In Taiwan,
data from cultured carp outbreaks showed mortality of 70–100% (Chen et al., 2015). Data on cases in
UK lakes supplied by the Centre for Environment, Fisheries and Aquaculture Science (Taylor, 2016)
show total mortalities occurred when water temperatures were in excess of 16°C, and were highly
variable between sites (ranging between 1 and > 2,000 in number). Percentage values associated with
these numbers are highly speculative, although thought to be around 10–20% on average; they could
be as high as 90% in exceptional circumstances. The duration over which mortality is observed is also
variable, but generally mortalities occur over a period of 12–20 days and is likely to be determined by
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the transmission dynamics occurring within a population and temperature. Gilad et al. (2004) showed
mortality to occur 5–8 days post-infection at 23–28°C, and Yuasa et al. (2008) showed mortality to
occur at 14–21 days post-infection at 16–18°C (Gilad et al., 2003; Yuasa et al., 2008). Omori and
Adams (2011) suggest that if infection occurs and the water temperature is subsequently reduced to
below 16°C the mortality rates are likely to be low. Seasonality in water temperatures is therefore
likely to be important in determining the level of mortality observed and the impact of the pathogen.
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
No cases of KHV in humans have been reported.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
At present, no treatments are available for KHV.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
A knowledge gap exists as little published information is available relating to the duration of virus
shedding by infected fish. Yuasa et al. (2008) conducted studies by infecting fish with KHV and mixing
them with na€ıve fish at different times post-infection. This study showed that fish could transmit the
virus at 34, 14 and 12 days’ post-exposure at 16, 23 and 28°C, respectively. Additionally, unpublished
studies by the UK’s Cefas suggest that fish exposed to KHV via bath challenge and then held
individually at 20°C begin shedding the virus between 1 and 4 days post-exposure, and, if they survive
infection can go on to shed virus up to day 25 post-exposure. However, in these experiments, 75% of
fish died and the 50% survival time was day 13 post-exposure.
Parameter 2 – Presence and duration of latent infection period
The experimental studies described in the above section suggest that no significant latent period is
observed in exposed fish prior to shedding, with virus being detected in fish mucous (i.e. shed) between
1 and 4 days post-exposure. Further research is required to confirm this and address the knowledge gap.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
Though a true latent period prior to shedding has not been proven and demonstrates a knowledge gap
requiring further study, long-term persistent infections have been demonstrated, and in common with
other herpes viruses, it seems likely that latency does occur. Serological testing of fish in lakes that
experienced clinical infections of KHV, show that seropositive fish could be detected 9 years post-
outbreak. Although the research did not demonstrate presence of the pathogen, this duration of antibody
persistence may suggest continued low level exposure to the virus and therefore persistence. This is
supported by published experimental studies that detected low levels of KHV DNA up to 2 months post-
infection in the gills, kidneys and brain of fish that survived primary infection and no longer showed clinical
signs (Gilad et al., 2004). Other studies also confirmed the presence of KHV DNA in the brain of fish for as
long as one year post-infection (Yuasa et al., 2012; Miwa et al., 2015). In wild populations, Uchii et al.
(2009) were able to detect KHV DNA in the brain of both seropositive and negative carp for over 2 years
post-outbreak. Reactivation of the virus in persistently infected fish had been demonstrated after moving
fish between sites and the application of temperature stress several months after exposure to the virus
(St-Hilaire et al., 2005; Bergmann and Kempter, 2011; Baumer et al., 2013). There is a knowledge gap
surrounding other factors that may induce recrudescence of the virus in latently infected fish.
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
KHV remains infectious in water for > 4 h, but < 21 h, at water temperatures of 23–25°C (Perelberg
et al., 2003). Other studies in Japan have displayed a significant reduction in the infectious titre of KHV
within 3 days in environmental water or sediment samples at 15°C, while the infectivity remained for
more than 7 days when KHV was exposed to sterilised water samples (Shimizu et al., 2006).
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In Japan, KHV DNA was detected in river water samples at temperatures of 9–11°C, 4 months prior
to a KHV disease outbreak being observed in a river (Haramoto et al., 2007). Using PCR based methods
KHV DNA has been detected at high levels in water samples collected at 8 sites along the Yura river
system during, and 3 months after a KHV disease outbreak at water temperatures ranging from 28.4
down to 14.5°C (Minamoto et al., 2009b). In Lake Biwa, Japan KHV was found to be widely distributed
throughout the lake 5 years after the first observed KHV outbreak. Mean concentrations of KHV in the
lake water showed annual variation, with a peak in the summer and a trough in winter, and the virus
was most prevalent in turbid, eutrophic water found in the lake margins (Minamoto et al., 2009a).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Vertical transmission has not been demonstrated to date and horizontal transmission is thought to
be the primary transmission route. Horizontal transmission of KHV could occur either by direct contact
between fish or by indirect transmission through the water. KHV can enter the host through skin or
pharyngeal periodontal mucosa (Raj et al., 2011; Fournier et al., 2012). Horizontal transmission in
natural ponds seems accentuated in hot spots of carp breeding behaviour and mating (Uchii et al.,
2011), where direct interactions between fish maybe high (Raj et al., 2011). Several potential vectors
could be involved in the indirect transmission of KHV including fish droppings (Dishon et al., 2005),
plankton (Minamoto et al., 2011), sediments (Honjo et al., 2012) and aquatic invertebrates feeding by
water filtration (Kielpinski et al., 2010). However, water is likely to be the dominant indirect
transmission route (Minamoto et al., 2009b), as KHV is shed into the environment from gills, skin and
gut and can remain infective in water and sediment for substantial periods (Perelberg et al., 2003;
Pikarsky et al., 2004; Dishon et al., 2005; Shimizu et al., 2006; Haramoto et al., 2007; Costes et al.,
2009; Minamoto et al., 2009a; Adamek et al., 2013).
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not applicable – KHV is not known to infect humans.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
No available data or published studies document a reliable time series of prevalence change in
natural infections; however, experimental studies suggest that as the pathogen is transmitted through
the water (in addition to via direct contact), infection rates post introduction are high and lead to the
majority of the population becoming infected over a period of a few days. The relatively short duration
of mortality observed in many natural outbreaks may also suggest that the majority of infection occurs
within a short timeframe.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
No available data or published studies allow R0 to be determined; however, as stated above, most of
the population apparently becomes infected over a few days and the limited timeframe over which
mortality is observed also suggests that most infection occurs within a short timeframe. No transmission
from fish to humans has been recorded and the virus is not thought to have any zoonotic potential.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
In Europe, reports of widespread mass mortality have been notified in carp farms and fisheries in
Germany, Poland and the UK (Bergmann et al., 2006; Taylor et al., 2010a,b; Gotesman et al., 2013).
The disease is also known to occur in, or has been recorded in fish imported into, Austria, Belgium,
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the Czech Republic, Denmark, France, Hungary, Italy, Luxembourg, the Netherlands, Ireland and
Switzerland (Haenen et al., 2004; Pokorova et al., 2010; McCleary et al., 2011; Pretto et al., 2013).
Most recently, KHVD outbreaks have been reported to the OIE from Romania, Slovenia, Spain and
Sweden (OIE, online). Three novel KHV-like viruses were also identified by PCR in the Netherlands, UK,
Austria and Italy. Carp carrying these KHV variants did not show clinical signs consistent with KHV
infection and originated from locations with no actual KHV outbreaks. In addition to these published
records, the OIE compiles the occurrence of KHV globally which can be viewed through the WAHIS1
interface. The results from this database are presented in Appendix A.
Risk of introduction
Parameter 3 – Routes of possible introduction
Worldwide trade in live common and koi carp is generally thought to be responsible for the spread
of the virus between countries. Spread is largely thought to have occurred prior to methods of
detection being available (OIE, online). The disease is now known to occur in, or has been reported in
fish imported into, at least 28 different countries (OIE, online). Susceptible species are traded for the
purpose of aquaculture, food and the ornamental trade. Controls are in place to prevent the
movement of fish for aquaculture and the ornamental trade from countries with the disease to those
confirmed free of the disease; however, these measure were only implemented after the pathogen was
listed in EU legislation. In the case of KHV, this occurred long after the pathogen emerged, meaning
few effective control procedures were in place early enough to prevent its rapid spread. Although fish
destined for the ornamental trade and as food commodities should not pose a risk to aquaculture or
fisheries, it is known that they are regularly introduced into open systems and therefore pose a
significant hazard (Taylor et al., 2011).
At a local level, the movement of live fish poses the greatest risk of spreading the pathogen;
however, the movement/transfer of water and equipment (such as anglers nets) may also contribute
to the spread of the pathogen.
Parameter 4 – Number of animal moving and/or shipment size
The movement and trade of live KHV susceptible species occurs for several purposes, including;
aquaculture, as a food commodity, the ornamental retail sector and direct supply of hobbyists. The
trading patterns are complex (Peeler and Taylor, 2011), Member States (MSs) will record imports and
movements for the purpose of aquaculture and possibly hold records of commodity trade; however,
these records only constitute a small amount of the relevant trade and are not stored in a centralised
repository and are therefore not readily available. Significant knowledge gaps relating to this section
therefore exist. In the UK, records of imports kept at each border inspection post (BIP) suggest that in
2006 4,684 consignments of coldwater ornamental fish (number and species unknown) were imported
into the main UK BIPs. These came from 116 different suppliers from across 12 non-EU countries
(Taylor et al., 2013). In comparison, trade in fish destined for aquaculture (or fisheries) in 2006 was
small, with only 93 consignments being imported, all of which originated in the EU. Movement of fish
within the UK in 2006 was more significant, with 2,642 movements of potentially susceptible fish
supplied by 426 UK sites to 1773 UK sites (Taylor et al., 2013).
Parameter 5 – Duration of infectious period in animal and/or commodity
As discussed in the above sections, although knowledge gaps relating to latency of KHV exist, the
best data available at present suggests fish exposed to the virus may remain infected for their lifetime.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
EU legislation (Council Directive 2006/88/EC2) prevents trade in fish species susceptible to listed
disease from countries with a lower health status than the receiving country. Countries listed as free
from KHV, or under an official control and eradication programme should therefore only receive fish
from approved KHV free countries. Import should occur through a BIP, where inspectors will check
that consignments of susceptible fish have a health certificate provided by the exporting country that
confirms they originate from a disease free compartment. Fish imported for the purpose of direct
consumption are exempt from these regulations, and may pose a risk if stocked or held in non-
1 http://www.oie.int/animal-health-in-the-world/the-world-animal-health-information-system/the-oie-data-system/
2 Council Directive 2006/88/EC of 24 October 2006 on animal health requirements for aquaculture animals and products thereof,
and on the prevention and control of certain diseases in aquatic animals. OJ L 328, 24.11.2006, p. 14–56.
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biosecure systems prior to slaughter. In addition to these international controls, testing at the BIPs to
confirm imported consignments are free from pathogens of concern constitutes a part of the EU
controls (e.g. KHV). It is not known how many countries employ such additional checks meaning a
knowledge gap exists, but given the volume of trade it is likely that only a small proportion of
consignments can be tested. Stockists of fish within MSs are encouraged to adopt good biosecurity
practices (such as quarantine) and ensure they know the origin of their stock, but a knowledge gap
exists relating to how frequently these recommendations are adhered to.
Parameter 7 – Presence and duration of latent infection and/or carrier status
As discussed in the above sections, fish exposed to the virus may remain infected for their lifetime.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Diagnosis of KHVD in clinically affected fish can be achieved by numerous methods. The manual of
diagnostic tests for aquatic animals lists gross clinical signs, histopathological alterations and
transmission electron microscopy as suitable for presumptive diagnosis of KHVD and descriptions of
these are documented in OIE (OIE, online). However, final diagnosis relies on direct detection of viral
DNA or virus isolation and identification (OIE, online). The OIE manual (OIE, online) details virus
detection methods that include single-round conventional PCR assays, virus isolation in cell culture,
indirect fluorescent antibody tests on kidneys imprints and formalin fixed paraffin wax sections
followed by confirmatory identification using PCR and nucleotide sequencing. Current virus isolation
and culture methods are not considered to be very sensitive, and are therefore not reliable for detection
of KHVD. None of the current diagnostic tests are fully validated and the manual suggests that diagnosis
of KHVD disease should not rely on just one test but rather a combination of two or three that include
clinical examination as well as virus detection (OIE, online). Non-destructive testing of fish relies on the
testing of blood. Pokorova et al. (2010), Bergmann et al. (2009) and Eide et al. (2011) applied PCR-
based methods to successfully detect KHV in the blood of infected carp, and Taylor et al. (2010a,b) an
applied antibody enzyme-linked immunosorbent assay (ELISA) to determine whether farmed, wild and
imported (Carp) in the UK had been exposed to the virus. Although it is likely that both approaches are
specific to KHV, a knowledge gap exists surrounding the sensitivity of these methods especially in the
case of sub-clinical infections (Bergmann et al., 2009; Pokorova et al., 2010; Taylor et al., 2010a;
Eide et al., 2011).
Control tools
Parameter 2 - Existence of control tools
No treatments for KHV exist, and control relies on preventing the introduction and spread of the
pathogen through a combination of good biosecurity, eradicating infected populations and applying
movement restrictions to infected sites. However, there is no published evidence on which to assess
the biological effectiveness or economic benefit of these generic approaches to disease control.
Modelling based studies by Taylor et al. (2011) suggest that in the case of the UK fish imported into
the country for the purpose of the ornamental trade and illegally stocked into fisheries are likely to
play a significant role in determining the effectiveness of control measures (Taylor et al., 2011).
Without controlling such introductions, the effectiveness of other control measures is likely to be
limited. This study also suggested that a high case detection rate (i.e. high diagnostic sensitivity,
including subclinical infections) was critical to an effective control strategy.
Alternative measures of control may be through an immunisation protocol (involving exposure to
live virus and water temperature manipulation) which was developed and has shown to be efficacious
(Perelberg et al., 2003; Ronen et al., 2003). A commercial attenuated vaccine has also been produced
(KoVac). Vaccination and immunisation of populations may also provide a useful tool as part of a
control and eradication programme.
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3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
In Europe, 18 MSs have reported KHV in some form. Reports of widespread mass mortality have
been notified in carp farms and fisheries in Germany, Poland and the UK (Bergmann et al., 2006;
Taylor et al., 2010a; Gotesman et al., 2013). The disease is also known to occur in, or has been
recorded in fish imported into, Austria, Belgium, the Czech Republic, Denmark, France, Hungary, Italy,
Luxembourg, the Netherlands, Ireland and Switzerland (Haenen et al., 2004; Pokorova et al., 2010;
McCleary et al., 2011; Pretto et al., 2013). Most recently, KHVD outbreaks have been reported to the
OIE from Romania, Slovenia, Spain and Sweden (OIE, online). Three novel KHV-like viruses have also
been identified by PCR in the Netherlands, UK, Austria and Italy. Although KHV is notifiable to the OIE,
reporting is down to the individual MSs and this is reliant on there being an effective means of
surveillance in each country so knowledge gaps may exist.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
In the 3 years since the first outbreak in Israel in 1998, KHVD spread to 90% of the carp farms
(Perelberg et al., 2003). By the end of 1998, the losses of common carp and ornamental carp were
estimated to be $1.2 million and $0.8 million annually. The loss of production of food carp in Israel in
1999 was estimated to be 1,500 tonnes (Mires, 2001).
In Japan, the disease first occurred in a lake used for common carp production, and in
approximately one month over 1,200 tonnes of fish had died, representing 25% of the annual
production of the lake (Sano et al., 2004a) with a value of approximately $2.55 million (Waltzek and
Hedrick, 2004). All remaining cultured carp in the lake were destroyed as a control measure
(Sano et al., 2004b). The disease has only been detected in common carp and not in koi carp in Japan
(Sano et al., 2004b).
Over 5,000 koi farmers in East Java were affected by the first outbreak of KHVD in Indonesia
(Sunarto et al., 2004) and the economic loss was estimated to be $0.5 million within the first three
months of the outbreak. The socioeconomic impact on affected communities was estimated to be $5
million in July of 2002, but by December of that year following the rapid spread of KHVD the figure
had doubled; as of December 2003 the losses were estimated to be $15 million.
In just two regions of Germany, the costs to three farms in 2003 were $435,500 and to one farm in
2004 was $417,000 (Schlotfeldt, 2004).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not applicable – KHV is not known to infect humans.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Fish infected with KHV and kept at a permissive temperature (i.e. > 16°C), die between 5 and 22 days
post-infection with peak of mortality occurring between days 8 and 12 post-infection (Hedrick et al.,
2000; Perelberg et al., 2003; Rakus et al., 2009; Fournier et al., 2012). Furthermore, KHV-infected fish
are more susceptible to secondary infections by bacterial, parasitic or fungal pathogens, which may
contribute to the mortalities observed in the infected population (McDermott and Palmeiro, 2013).
The first clinical signs usually appear 2–3 days post-infection. In carp, severe necrosis of the gills is
the major clinical sign (likely the predominant cause of death), but they also generally express the
following: folding of the dorsal fin; increased respiratory frequency; gathering near well-aerated areas;
skin changes including gradual hyperaemia at the base of fins, increased (sometimes decreased)
mucus secretion, haemorrhages and ulcers on the skin, sloughing of scales and fin erosion, sandpaper-
like texture of the skin, skin herpetic lesions; gasping at the water surface; lethargy (lying at the
bottom of the tank, hanging in head-down position in the water column) associated with anorexia;
sunken eyes; neurological symptoms with erratic swimming and loss of equilibrium (Walster, 1999;
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Hedrick et al., 2000; McDermott and Palmeiro, 2013; Rakus et al., 2013). None of these clinical signs
are specific to KHV disease.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
None of the susceptible species listed are classed as endangered.
Parameter 2 – Mortality in wild species
Although carp (and its variants) are widely cultured or stocked, in many countries they can also be
regarded as a wild species. In the case of natural infections in open water systems, although several
studies suggest that mortality due to KHV (in lake and farm systems) can be high, knowledge gaps
exist as due to difficulties in determining the total host population size, thus no reliable estimates of
percentage mortality are available in case sites. In Taiwan, data from cultured carp outbreaks showed
mortality of 70–100% (Chen et al., 2015); however, information on mortality rates in Europe is limited.
Data on cases in the UK lakes supplied by Cefas (Taylor, 2016) show total mortalities to occur when
water temperatures were in excess of 16°C, and to be highly variable between sites (ranging between
1 and > 2,000). Percentage values surrounding these figures are highly speculative, but were thought
to be around 10–20% on average, but could be as high as 90% in exceptional circumstances. The
duration over which mortality was observed is also variable, but generally occurred over a period of
12–20 days. The duration over which mortality occurs is likely to be determined by the transmission
dynamics occurring within a population and temperature.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
Fish surviving infection by KHV are likely to remain carriers for life (discussed in sections above);
however, even in the absence of infected fish the virus may persist in the sediment for some time,
posing a risk of subsequent infection (see Section 3.1.1.5 Parameter 4). For example, in Japan, using
PCR detection methods to screen environmental water samples, KHV was detected at high levels at 8
sites along the Yura river system during, and 3 months after an episode of mass mortality caused by
KHV disease. KHV was also found to be widely distributed throughout Lake Biwa, Japan 5 years after
the first observed KHV outbreak (Minamoto et al., 2009a, 2012; Uchii et al., 2009, 2011).
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classification of pathogens
KHV is an OIE listed pathogen.
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
It is not listed.
Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
It is not listed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Officially/internationally recognised diagnostic tool, OIE certified
The KHV chapter in the OIE Diagnostic manual (OIE, online) provides information on the most
commonly used quantitative assay for detection of KHV, the Gilad Taqman real-time PCR assay (Gilad
et al., 2004). Real-time Taqman PCR is now a very common diagnostic procedure that has been shown
to detect and quantitatively assess very low copy numbers of target nucleic acid sequences.
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Furthermore, Taqman PCR avoids much of the contamination risk inherent to nested PCR assays by
minimising the handling of samples through automation during sample preparation and thermal cycling
procedures.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Bergmann et al. (2010a–c) compared existing and newly developed PCRs for the detection of KHV
DNA (Bergmann et al., 2010c). A modified real-time PCR (Gilad et al., 2004), combined with an
internal control system (IC2), was used as a reference standard. The most sensitive PCR assays,
capable of detecting 5–10 KHV DNA genomic equivalents, were the Gilad Taqman real-time qPCR, a
nested Bergmann/Gilad assay (Bergmann et al., 2006) and a newly-developed, one tube semi-nested
PCR. In term of analytical specificity, the PCR assays were tested against carp pox virus, goldfish
herpesvirus, channel catfish herpesvirus and herpesvirus anguillae, and they recognise KHV only.
Measures of diagnostic sensitivity and specificity of this PCR assays are not reported.
The Bergmann study also discovered ‘KHV variants’ in two field samples which could not be
detected by the Bercovier TK PCR. Also a negative influence of sample pooling was shown with field
samples tested by real-time PCR. However, the comparative testing mostly used KHV DNA in plasmids
and extracted from KHV-infected cell cultures. The field samples were comprised of 18 KHV-infected
carp and 3 KHV-exposed carrier fish. The Bercovier TK PCR assays compared in this study (single-
round and nested) were run with an annealing temperature of 55°C. This is a higher temperature than
the 52°C stated in the original paper (Bercovier et al., 2005) and may account for the lack of sensitivity
shown by these assays.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
According to the OIE manual (OIE, online): ‘Gill, kidney, and spleen are the organs in which KHV is
most abundant during overt infection’ and should therefore be targeted.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
An inactivated vaccine candidate exists that consists of formalin-inactivated KHV contained in a
liposomal compartment (Yasumoto et al., 2006). A conventional anti-KHV attenuated vaccine has also
been developed which is used commercially in Israel (produced by KoVac); this is however pathogenic
to small fish and there is the possibility of reversion to a pathogenic phenotype (Yasumoto et al.,
2006). The development of alternative attenuated recombinant vaccines is also being investigated
(Boutier et al., 2015).
Parameter 2 – Availability/production capacity (per year)
This is unknown and constitutes a knowledge gap.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
Inactivated vaccine reduces mortality by 70% (Yasumoto et al., 2006).
Parameter 4 – Duration of protection
This is unknown and constitutes a knowledge gap.
Feasibility
Parameter 5 – Way of administration
Inactivated vaccine administered through feed (oral), attenuated administered by immersion in
water (bath).
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3.1.4.3. Article 7(d)(iii) Medical treatments
There is no available medical treatment.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Parameter 1 – Available biosecurity measures
Biosecurity to prevent introduction of the pathogen from live fish centres around safe sourcing of
stock from known disease free origin. Testing of consignments upon receipt and prior to introduction
to other stocks is at the discretion of the receiving country or site. Quarantining stock on arrival is
complicated by latency and the existence of permissive temperatures. Heat ramping to induce viral
shedding may be required in addition to the use of na€ıve sentinel fish for quarantine to be an effective
biosecurity measure.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Safe sourcing of fish is the most effective measure, but this is complicated by the fact that fish
surviving infection show no clinical signs of disease and may carry virus at such low levels they are
difficult to detect by molecular methods. Serological testing may provide additional assurance that fish
are free from KHV, though the specificity of current serological tests needs further evaluation. Fish that
have survived clinical infection are unlikely to re-express clinical signs during quarantine, therefore this
measure is likely to have little value unless used in combination with sentinel fish and a stressor (such
as heat ramping) to induce recrudescence of the virus.
Feasibility
Parameter 3 – Feasibility of biosecurity measure
The complexity of both international and national trading patterns of cyprinids, in addition to
interactions between different industry sectors, can make it difficult to be sure of the origin of fish.
Testing consignments of fish on arrival at border inspection posts is feasible, but the volume of trade
means that only a small proportion of fish are likely to be tested. Additionally, there are logistical
issues with holding fish in biosecure conditions to good welfare standards whilst awaiting test results
for the purpose of quarantine.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
At the international level, Council Directive 2006/88/EC3 allows the restriction of imports of fish
from countries with a lesser health status with regard to KHV than the receiving country. To date,
however, only three countries within the EU have been recognised as KHV free (commission
Implementing Decision (EU) 2015/13104), and therefore very few countries can restrict the import of
susceptible species from known KHV positive countries. At the national level, movement restrictions
can be applied to KHV positive sites, which should remain in force until the site has depopulated and
disinfected to the satisfaction of the competent authority, or has gone through at least 4 consecutive
years of testing negative for the virus and showing no signs of clinical disease. Additional biosecurity
measures such as disinfectant baths should also be introduced to sites under such circumstances.
These controls all rely on an effective surveillance, testing and reporting system.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
Cefas have observed very little recurrence of disease at KHV positive sites suffering clinical
outbreaks of KHV in the UK. However, the effectiveness of movement restrictions is complicated by the
3 Council Directive 2006/88/EC of 24 October 2006 on animal health requirements for aquaculture animals and products thereof,
and on the prevention and control of certain diseases in aquatic animals. OJ L 328, 24.11.2006, p. 14–56.
4 Commission Implementing Decision (EU) 2015/1310 of 28 July 2015 amending Annex I to Decision 2009/177/EC as regards
disease-free status for the whole territory of Croatia for koi herpes virus (KHV) disease (Text with EEA relevance). OJ:
JOL_2015_200_R_0008
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potential for latency of the virus in surviving stock. Taylor et al. (2010a,b) demonstrated that KHV
seropositive sites could be traced back to other seropositive sites. Whether such movements lead to
the expression of clinical disease is likely to be depend on whether the fish are still infected and
several climate (e.g. temperature) and site level factors (stock density at receiving site) at the time fish
are transferred. If fish are moved whilst the temperature is below 16°C and/or stock densities at the
receiving site are low, clinical disease may not occur and the virus could potentially spread silently.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
The ability to apply movement restrictions will vary depending on the resources available within
each MS to perform and effective surveillance and detection program, and, enforce movement
restrictions and measures applied to infected sites.
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
A questionnaire sent to EU MSs asking about methods used for slaughter of carp found that the
following methods were commonly used: asphyxia following percussion, electrical stunning and
percussion. In the context of disease controls, carp farms can be destocked netting the fish into tanks
where they can be euthanised using an overdose of anaesthetic, e.g. MS222 or phenoxiethanol (it
should be noted that there is no product licensed in Europe to our knowledge for euthanasia).
Alternatively, percussive stunning (using a ‘priest’) can be used prior to killing by slitting the gills (or
evisceration). This method is used commercially. Captive bolt methods are under development.
Electrical stunning is possible but in general devices are not widely available. Methods of killing are
covered in detail in an EFSA paper (Algers et al., 2009).
In extensive ponds and stillwater fisheries removal of all fish, prior to slaughter, requires the water
to be drained. The hydrology and soil type means this is impractical in many situations. Farmers may
seek to harvest fish for human consumption to reduce financial losses. These fish must be slaughtered
and processed in approved premises so that processing waste is disposed of in a biosecure manner.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
Killing and removal of fish from an infected farm effectively eliminates further contamination of the
water, equipment, etc., and thus is effective in reducing spread of the disease via water or fomite
transmission. Water, sediment, etc. will remain contaminated, if the site is not emptied, cleaned and
disinfected, and thus a source of infection for a period after the farm has been destocked. Killing by
exsanguination or evisceration will result in further contamination and in this respect is less preferable
than an overdose of anaesthetic.
Feasibility
Parameter 3 – Feasibility of killing animals
Killing using an overdose of an anaesthetic (e.g. MS222) administered to fish kept in small volumes
of water is the most feasible method available. Detailed protocols setting tank sizes and dosing per
biomass of fish are not publicly available. Percussion stunning using a ‘priest’ followed by
exsanguination or evisceration is most suitable for small numbers of fish. Electrical stunning is feasible
if the appropriate equipment is available, and they are not widely used. A knowledge gap exists as
there are no published data comparing rates of slaughter by different methods.
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3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Health rules for animal by-products and derived products (repealing Regulation (EC) No 1774/20025),
fish killed for the control of a listed disease constitute category I waste. Category I waste must be
rendered at an approved establishment. A list of approved premises by MS can be found at http://ec.
europa.eu/food/safety/animal-by-products/approved-establishments/index_en.htm. Carcasses must be
transported to an approved premise by approved transport in a sealed container.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Rendering is an extremely effective disposal method of destroying pathogens. Rendering converts
waste animal tissue into stable, value added products. The process simultaneously dries the material
and separates the fat from the bone and protein. Tissues are macerated, heated and then subject to
centrifugal separation.
Feasibility
Parameter 3 – Feasibility of disposal option
Rendering is a feasible option if an approved establishment is located within a reasonable distance
from the farm, is willing to accept fish carcasses and approved transport is available.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
A knowledge gap exists as there are no published data on the cost of control of KHV. There are no
treatments and no vaccine has been licensed in Europe. Biosecurity for KHV on carp farms include
measures to prevent introduction on fomites, e.g. foot baths, cleaning of vehicles entering the site,
disinfection of equipment entering the site etc. These measures are part of good management and are
not specific to KHV. Purchasing stock from known KHV free sites is the key biosecurity measure to
maintain freedom from KHV. The supply of stock from approved free premises may be limited and
more costly than stock from non-approved sites, however, no data are available on which to asses a
price differential. A purchaser could require stock to be tested prior to purchase. This is an expensive
option and probably not viable except for high value ornamental carp.
Parameter 2 – Cost of eradication (culling, compensation)
There are no published data for the costs associated with eradication. They will, however, depend
on the size and structure of a site. Many carp farms in Europe are very large scale (with ponds
covering more than one hectare). Eradication is technically challenging and very time consuming.
Netting and killing the fish would take a team of four qualified staff up to 5 days. Based on the
experience in the UK, the total cost including disposal is likely to be in the region of 20,000 euros. A
smaller farm where carp are raised in accessible ponds can be destocked for half this amount. Most
MS do not pay compensation. Large carp produced for angling in the UK are valuable. A 10-kg fish
costs approximately £750, while small carp at round 5 kg are sold for £100. Carp produced for the
table have a lower value. Farmgate prices for carp in Europe were not available but it retails at about
2.5 euros per kg.
Parameter 3 – Cost of surveillance and monitoring
Under Council Directive 2006/88/EC,3 the competent authority has an obligation to undertake
authorisation visits to farms on a regular basis. While these activities are an important element of
surveillance, the costs cannot be attributed to a single disease. The key obligation of competent
5 Regulation (EC) No 1774/2002 of the European Parliament and of the Council of 3 October 2002 laying down health rules
concerning animal by-products not intended for human consumption. OJ L 273, 10.10.2002, p. 1–95.
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authorities is to investigate suspected cases of KHV. The cost of a single investigation including
diagnostics is approximately 1000 euros. In the UK, 30–80 outbreaks are investigated each year at a
cost of 30–80,000 euros.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
KHV is listed under EU legislation and it is also notifiable to the OIE. EU MS can establish approved
free compartments, zones and countries and then restrict trade in susceptible species (e.g. carp) to
zones of the same status. However, very little carp production in the EU is in approved free areas.
Internationally the picture is the same – very little production takes place in areas self-declared free.
Effectively, there has been very little economic impact via trade loss due to KHV within the EU or
internationally.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
In the UK, KHV has impacted carp fisheries (farms have largely been unaffected). Outbreaks occur
on 10–24 fisheries per year, causing losses of upwards of 10% of carp. There are approximately over
5,000 carp fisheries in the UK. Thus, the impact of the disease compared to the size of the sector is
negligible. An individual fishery suffers direct losses due to mortality and the implementation of control
measures (including restrictions on stocking). These losses have not been estimated, however, they
have not resulted in any fishery ceasing to trade to date. It was estimated that in Germany the costs
of an outbreak in a farm producing 20 tonnes of fish ranges from €150,000 to €250,000 (including
disinfection, removal of carcasses, cleaning and partly restocking) (Brauer et al., 2004).
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
No published studies on the societal acceptance of disease prevention and control measures for
KHV were found. In the UK, disease control measures on carp fisheries, farms and in ornamental fish
retailers are widely accepted by stakeholders. At a societal level, there has been little opposition to
destocking of farms or fisheries undertaken as part of a disease control programme.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Holding fish for the purpose of quarantine or whilst awaiting test results relies on having suitable
biosecure systems to hold the fish in a sustainable manner. Such systems must have sufficient space to
hold the stock, have the ability to feed the fish and maintain the environmental quality of the water
they are held in. Where the virus is detected and the decision is made to cull the stock, care must be
taken to employ a suitable humane method that can be applied to a potentially high number of fish. In
many countries, the availability of suitable holding facilities and/or high throughput culling methods
may be limited.
Parameter 2 – Wildlife depopulation as control measure
Due to the extensive nature of the systems containing wild carp populations and dependency on
the water they live in for other purposes (e.g. drinking, recreation, etc.), depopulation of sites using
biocides is not likely to be feasible. In small self-contained waters, biocides may be applied or the site
depopulated trough draining or other methods (e.g. netting).
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Not applicable.
Biodiversity
Parameter 2 – Mortality in wild species
In many European countries, carp can be classed as both a domestic and wild species and there is
a great degree of interaction between the two population types. Many of the outbreaks recorded to
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date have occurred in fishery/lake populations of carp, so the impact to these wild/semiwild
populations can be as great as observed in farms (Taylor et al., 2010a,b).
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about KHVD (Table 1). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW Panel,
2017). Experts have been provided with information of the disease fact-sheet mapped into Article 5
criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’
judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 10. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 2–4). The proportion of Y, N or na answers are reported, followed
by the list of different supporting views for each answer.
Table 1: Outcome of the expert judgement on the Article 5 criteria for Koi herpes virus disease
(KHVD)
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist
in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at point A(i)–A(v), the disease needs to fulfil at least one of the following
criteria
B(i) The disease causes or could cause significant negative effects in the Union on animal
health, or poses or could pose a significant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a significant danger to
public and/or animal health in the Union
na
B(iii) The disease causes or could cause a significant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a significant negative impact on the environment, including
biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufficient evidence or
not relevant to judge.
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Reasoning supporting the judgement
Supporting Yes:
• Biosecurity and movement controls limit the spread. At least 18 MSs have reported the
detection of KHV.
• There is a very little recurrence of disease where it has been previously diagnosed.
• The impact of the disease compared to the size of the sector is negligible and therefore the
measures are proportionate.
• Diagnosis of KHV in clinically affected fish relies on numerous methods, as described in the OIE
manual of diagnostic tests for aquatic animals.
• If clinical signs are apparent, the disease can be detected.
Supporting No:
• Current available diagnostic tools and treatments are limited. Vaccines are not available in the
EU. None of the current diagnostic tests are fully validated: the level of sensitivity of these
methods is still unclear, especially in the case of subclinical infections.
• There is a high risk of subclinical infections despite the control measures available.
Reasoning supporting the judgement
Supporting Yes:
• There may be an impact on biodiversity considering wild carp, although none of the
susceptible species listed are classed as endangered.
• Carp is an allochthonous species, the disease may spread to and among native fish.
Supporting No:
• Apparently, there is no or little recurrence after an outbreak despite long persistence of the
virus in the environment and fish being tested positive, thus there is no long-term impact.
3.2.2. Outcome of the assessment of Koi herpes virus disease (KHV) according
to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulfils all criteria of the first set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulfilled when the outcome is ‘Yes’. According to the results shown in Table 1, KHVD
complies with criteria A(i), A(ii), A(iii) and A(iv) and the assessment is inconclusive on compliance with
Table 2: Outcome of the expert judgement related to criterion 5 A(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
A(v) Risk-mitigating measures and, where relevant,
surveillance of the disease are effective and
proportionate to the risks posed by the disease
in the Union
NC 90 10 0
NC: non-consensus; number of judges: 10.
Table 3: Outcome of the expert judgement related to criterion 5 B(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(v) The disease has or could have a significant
negative impact on the environment,
including biodiversity, of the Union
NC 80 20 0
NC: non-consensus; number of judges: 10.
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criterion 5 A(v). Therefore, it is inconclusive whether KHVD can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about KHVD (Tables 4–8). The expert judgement was based on
ICBA approach described in detail in the opinion on the methodology. Experts have been provided with
information of the disease fact-sheet mapped into Article 9 criteria (see supporting information, Annex
A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9, and
the reasoning supporting their judgement. The minimum number of judges in the judgement was 10.
The expert judgement was conducted as described in the methodological opinion (EFSA AHAW Panel,
2017). For details on the interpretation of the questions, see Appendix B of the methodological opinion
(EFSA AHAW Panel, 2017).
Table 4: Outcome of the expert judgement related to the criteria of section 1 of Annex IV
(category A of Article 9) for Koi herpes virus disease (KHVD)
Criteria to be met by the disease:
The disease needs to fulfil all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional cases
(irregular introductions) OR present in only in a very limited part of the territory of the
Union
NC
2.1 The disease is highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and significant mortality rates NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulfil at least one of the following
criteria
3 The disease has a zoonotic potential with significant consequences on public health,
including epidemic or pandemic potential OR possible significant threats to food safety
N
4 The disease has a significant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a) The disease has a significant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a significant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a significant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a significant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term damage
to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Table 5: Outcome of the expert judgement related to the criteria of section 2 of Annex IV
(category B of Article 9) for Koi herpes virus disease (KHVD)
Criteria to be met by the disease:
The disease needs to fulfil all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free of
the disease
N
2.1 The disease is moderately to highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulfil at least one of the following
criteria
3 The disease has a zoonotic potential with significant consequences on public health,
including epidemic potential OR possible significant threats to food safety
N
4 The disease has a significant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a) The disease has a significant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a significant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a significant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a significant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term damage
to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 6: Outcome of the expert judgement related to the criteria of section 3 of Annex IV
(category C of Article 9) for Koi herpes virus disease (KHVD)
Criteria to be met by the disease:
The disease needs to fulfil all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character OR in aquatic animals several Member States or zones of the Union are free of
the disease
NC
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND
often the most observed effect of the disease is production loss OR in aquatic animals the
disease may result in high morbidity and usually low mortality AND often the most observed
effect of the disease is production loss
NC
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 9–13).
The proportion of Y, N or `na0 answers are reported, followed by the list of different supporting views
for each answer.
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulfil at least one of the following
criteria
3 The disease has a zoonotic potential with significant consequences on public health, or
possible significant threats to food safety
N
4 The disease has a significant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
Y
5(a) The disease has a significant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a significant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a significant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a significant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term damage
to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 7: Outcome of the expert judgement related to the criteria of section 4 of Annex IV
(category D of Article 9) for Koi herpes virus disease (KHVD)
Criteria to be met by the disease:
The disease needs to fulfil all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
NC
The disease fulfils criteria of section 1, 2, 3 or 5 of Annex IV of AHL NC
Colour code: yellow = no consensus (NC).
Table 8: Outcome of the expert judgement related to the criteria of section 5 of Annex IV
(category E of Article 9) for Koi herpes virus disease (KHVD)
Diseases in category E need to fulfil criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment
(If a disease fulfils the criteria as in Article 5, thus being eligible to be listed, consequently
category E would apply.)
NC
Colour code: yellow = no consensus (NC).
Table 9: Outcome of the expert judgement related to criterion 1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
1 (cat.A) The disease is not present in the territory
of the Union OR present only in exceptional
cases (irregular introductions) OR present in only
in a very limited part of the territory of the Union
NC 10 90 0
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Reasoning supporting the judgement
Supporting Yes for 1 (cat.A):
• There is only irregular incursion.
Supporting Yes for 1 (cat.C):
• Most EU MSs are infected – only three of them are free and they have low fish production.
Supporting Yes for 1 (cat.CAq):
• According to the current distribution of endemic infected/ free countries at EU level, several
MSs are free.
• There are only irregular incursions, leading to stamping out.
Reasoning supporting the judgement
Supporting Yes for 2.1 (cat.A):
• There is an observation of high mortality and high infection rates a few days after the
introduction of the virus.
Supporting Yes for 2.1 (cat.B,C):
• Based on detection in most MSs but little impact reported despite longevity of the virus and
lack of treatment availability, there is not always a high transmissibility.
• R0 is unknown, so there is no clue that transmissibility is always high.
Table 10: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.1 (cat.A) The disease is highly transmissible NC 70 30 0
2.1 (cat.B,C) The disease is moderately to highly transmissible NC 30 70 0
NC: non-consensus; number of judges: 10.
Question
Final
outcome
Response
Y (%) N (%) na (%)
1 (cat.C) The disease is present in the whole OR
part of the Union territory with an endemic character
NC 10 90 0
1 (cat.CAq) In aquatic animals, several Member States
or zones of the Union are free of the disease
NC 80 20 0
NC: non-consensus; number of judges: 10.
Table 11: Outcome of the expert judgement related to criterion 2.4 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.4 (cat.A) The disease may result in high morbidity
and significant mortality rates
NC 80 20 0
2.4 (cat.B) The disease may result in high morbidity
with in general low mortality
NC 10 90 0
2.4 (cat.CAq) In aquatic animals, the disease may result
in high morbidity and usually low mortality
AND often the most observed effect of the
disease is production loss
NC 10 90 0
NC: non-consensus; number of judges: 10.
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Reasoning supporting the judgement
Supporting Yes for 2.4 (cat.A):
• Based on mortality estimated from field (10–20%) and experimental morbidity (100%).
Supporting Yes for 2.4 (cat.B):
• Based on the long-term position, even when an outbreak initially had high mortality. Fish that
survive primary infection no longer show clinical signs. The best data available at present
suggests fish exposed to the virus may remain infected for their lifetime.
Supporting Yes for 2.4 (cat.CAq):
• Morbidity is high, mortality is generally low, particularly when water temperatures are below
16°C, and only in the initial phase of the outbreak it can be high and even then it can be very
variable. The disease leads to losses in the aquaculture production during an outbreak. Fish
that survive primary infection no longer show clinical signs. In wild populations, KHV has been
found in the brain of both seropositive and negative carp for over two years post outbreak.
Serological testing of lakes that experienced clinical infections of KHV show that seropositive
fish could be detected 9 years post-outbreak suggesting continued low level exposure to the
virus and therefore persistence. The best data available at present suggests fish exposed to
the virus may remain infected for their lifetime. In the UK, KHV has impacted carp fisheries
(farms have largely been unaffected). Outbreaks occur on 10–24 fisheries per year, causing
losses of upwards of 10% of carp. There was no information indicating that any fishery to
date, in Europe, had ceased to trade because of KHV.
Reasoning supporting the judgement
Supporting Yes:
• This is linked to high morbidity and mortality.
Supporting No:
• There may be high mortality with newly introduced infection, but apparently little thereafter
despite continuing test positive detections.
Table 12: Outcome of the expert judgement related to criterion 5(b) of Article 9
Question*
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a significant impact on animal welfare,
by causing suffering of large numbers of animals
NC 80 20 0
NC: non-consensus; number of judges: 10.
*At the time of the collective judgement the assessment of the current impact considering the control measures in place was
considered.
Table 13: Outcome of the expert judgement related to criterion D of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
D The risk posed by the disease in question can be
effectively and proportionately mitigated by measures
concerning movements of animals and products in
order to prevent or limit its occurrence and spread
NC 70 30 0
NC: non-consensus; number of judges: 10.
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Reasoning supporting the judgement
Supporting Yes:
• The control relies on preventing the introduction and spread of the pathogen through a
combination of good biosecurity, eradicating infected populations and applying movement
restrictions to infected sites.
• Very little recurrence of disease has been observed at KHV positive sites suffering clinical
outbreaks of KHV in the UK. However, the effectiveness of movement restrictions is
complicated by the potential for latency of the virus in surviving stocks.
Supporting No:
• There are limited diagnostic tests available at EU level and they have a poor sensitivity. Silent
spread of the virus through undetected infected animals not showing clinical signs is possible.
• Field experience shows that spread does occur in spite of control efforts.
3.3.2. Outcome of the assessment of criteria in Annex IV for Koi herpes virus
(KHV) disease for the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered fitting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulfils all criteria of the first set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 5–9. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulfilled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for KHV disease for the
purpose of categorisation as in Article 9 of the AHL is presented in Table 14.
According to the assessment here performed, KHVD complies with the following criteria of the
sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the first set
(1, 2.1–2.4) and according to the assessment KHVD complies with criteria 2.2 and 2.3,
whereas the assessment is inconclusive on compliance with criteria 1, 2.1 and 2.4. To be
eligible for category A, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and KHVD does not comply with criteria 3, 4, 5a, 5c and 5d, and the
assessment is inconclusive on compliance with criterion 5b.
2) To be assigned to category B, a disease needs to comply with all criteria of the first set
(1, 2.1–2.4) and according to the assessment KHVD complies with criteria 2.2 and 2.3, does
not comply with criterion 1 and this assessment is inconclusive on compliance with criteria
Table 14: Outcome of the assessment of criteria in Annex IV for KHV disease for the purpose of
categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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2.1 and 2.4. To be eligible for category B, a disease needs to comply additionally with one of
the criteria of the second set (3, 4, 5a–d) and KHVD does not comply with criteria 3, 4, 5a,
5c and 5d, and this assessment is inconclusive on compliance with criterion 5b.
3) To be assigned to category C, a disease needs to comply with all criteria of the first set
(1, 2.1–2.4) and according to the assessment KHVD complies with criteria 2.2 and 2.3,
whereas the assessment is inconclusive on compliance with criteria 1, 2.1 and 2.4. To be
eligible for category C, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and KHVD complies with criterion 4, does not comply with criteria 3,
5a, 5c and 5d, and this assessment is inconclusive on compliance with criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of section 1, 2, 3 or 5
of Annex IV of the AHL and with the specific criterion D of section 4, whose assessment for
KHVD is inconclusive.
5) To be assigned to category E, a disease needs to comply with criteria of section 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating to
animal health, animal welfare, human health, the economy, society or the environment. The
latter is applicable if a disease fulfils the criteria as in Article 5 and the assessment here
performed for KHVD is inconclusive on compliance with the criteria as in Article 5.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
KHVD. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a specific listed disease because:
a) they are susceptible for a specific listed disease or scientific evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientific evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.6 According to the
mapping, as presented in Table 5, section 3.2 of the scientific opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for KHVD according to the criteria of
Article 8(3) of the AHL are as displayed in Table 15.
6 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, it is inconclusive whether KHVD can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
Eligibility of listing KHVD is dependent on a decision on criterion 5 A(v).
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, since it is inconclusive whether KHVD can be
considered to be listed for Union intervention as laid down in Article 5(3) of the AHL, then also
the assessment of its compliance with each of the criteria in Annex IV to the AHL for the
purpose of categorisation of diseases in accordance with Article 9 of the AHL is inconclusive.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
Table 15: Animal species to be listed for Koi herpes virus disease (KHV) according to criteria of
Article 8 (source: data reported in Section 3.1.1.1)
Phylum Class Order Family Genus/Species
Susceptible Chordata Actinopterygii Cypriniformes Cyprinidae Cyprinus carpio and
its varieties,
Carassius auratus,
Carassius carassius
Reservoir Mollusca Bivalvia Unionoida Not specified Not specified
Arthropoda
(subphylum:
Crustacea)
Not specified Not specified Not specified Not specified
Chordata Actinopterygii Cypriniformes Cyprinidae Carassius auratus,
Ctenopharyngodon
idella,
Tinca tinca,
Vimba spp.,
Abramis brama,
Rutilus rutilus,
Scardinius
erythrophthalmus,
Carassius gibelio,
Hypophthalmichthys
molitrix,
Leuciscus idus,
Gobioninae
Perciformes Percidae Perca fluviatilis,
Gymnocephalus cernua
Eleotridae Not specified
Microdesmidae
(subfamily:
Ptereleotrinae)
Not specified
Esociformes Esocidae Esox lucius
Siluriformes Not specified Not specified
Acipenseriformes Acipenseridae Acipenser
gueldenstaedtii,
Acipenser oxyrinchus
Vectors None
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• According to the assessment here performed, since it is inconclusive whether KHVD can be
considered to be listed for Union intervention as laid down in Article 5(3) of the AHL, then it is
also inconclusive which animal species can be considered to be listed for KHV disease
according to Article 8(3) of the AHL.
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Appendix A – Table of global occurrence of KHV according to the OIE
WAHIS database
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/Diseasetimelines
Key to colours 
  There is no information available on this disease 
  Never reported 
  Disease absent 
  Disease suspected but not confirmed 
  Infection/infestation 
  Disease present 
  Disease limited to one or more zones 
  Infection/infestation limited to one or more zones 
  Disease suspected but not confirmed and limited to one or more zones
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